New hope for Tough-to-Treat lung cancer: targeted drug enters final testing phase
NCT ID NCT06930794
Summary
This study is testing whether adding a new oral drug called vebreltinib to standard chemotherapy works better than chemotherapy alone for people with advanced non-squamous non-small cell lung cancer (NSCLC) who have a specific genetic feature called MET-positive. The trial aims to see if the combination helps control the cancer for longer and is safe for patients who haven't had prior treatment for their advanced disease. It is a large, late-stage study recruiting about 300 participants at multiple locations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.